Our study observed attenuated expression of ATP6AP1L in the basal-like and Her2+ subtypes of the breast cancer samples compared to normal breast tissues and a shorter recurrence-free survival time with the lower expression group in most subtypes of breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.